ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0354

How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study

Uta Kiltz1, Jan Brandt-Jürgens2, Peter Kästner3, Elke Riechers4, Daniel Peterlik5 and Hans-Peter Tony6, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 2Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, 3Ambulantes Rheumazentrum, Erfurt, Germany, 4Hannover Medical School, Hannover, Germany, 5Novartis Pharma GmbH, Nürnberg, Germany, 6Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), Anti-TNF Drugs, Biologicals, Disease Activity, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there is lack of real-world evidence on SEC treatment outcomes, disease activity, physical functioning and on its retention, especially in anti-tumor necrosis factor (anti-TNF) naïve patients and patients pretreated with different anti-TNFs in medical history.1

The aim of this interim analysis is to evaluate SEC treatment outcomes on disease activity, physical functioning and retention rates in AS patients stratified by number of anti-TNFs (naive, 1 or ≥2) in medical history.

Methods: AQUILA is an ongoing, multi-center, non-interventional study. AS and psoriatic arthritis patients treated with SEC in daily practice are enrolled and observed from baseline (BL, d0 or d1 of study start) up to week 52 according to clinical routine. Real-world effectiveness of SEC was assessed prospectively and analyzed as observed. Here, we report interim results of SEC effectiveness on different treatment outcomes in AS patients by means of validated questionnaires such as patient´s global assessment (PGA), Bath Ankylosing Disease Activity Index (BASDAI), and Assessment of Spondyloarthritis Health Index (ASAS-HI). In addition, retention rates (time from study inclusion until premature SEC treatment discontinuation) were assessed through Kaplan-Meier plots. This interim analysis focuses on anti-TNF naïve and AS patients treated with 1 anti-TNF or ≥2 anti-TNFs in medical history. Wilcoxon tests were conducted to show significant differences between the subgroups.

Results: At BL, 311 AS patients were included; 72 (23.2%) of them received SEC already for more than 1 day up to more than 6 months before BL. Most AS patients were anti-TNF-experienced (71.1%): 82 (26.4%) and 139 (44.7%) AS patients had 1 or ≥2 prior anti-TNF treatments, respectively. BL scores for PGA, BASDAI and ASAS-HI were similar between the different anti-TNF subgroups. Constant improvement was shown in all parameters from BL up to week 52, irrespective of prior anti-TNF treatment (PGA-anti-TNF naïve: 5.9 to 3.5, PGA-1 anti-TNF: 6.1 to 4.2 and PGA-≥2 anti-TNFs: 6.7 to 5.1; BASDAI-anti-TNF naïve: 5.3 to 3.4, BASDAI-1 anti-TNF: 5.5 to 3.7 and BASDAI-≥2 anti-TNFs: 5.7 to 4.7). However, overall better improvement was observed in anti-TNF naïve patients, as seen by the example of ASAS-HI (Fig. 1). Between 30% and 40% of patients prematurely discontinued SEC treatment in the subgroups 1 anti-TNF and ≥2 anti-TNFs, respectively, while only about 20% did so in the anti-TNF naïve AS patients (Fig. 2).

Conclusion: SEC has shown to improve disease activity, physical functioning and QoL in anti-TNF-naïve and pretreated AS patients in a real-world setting. The benefits of SEC were numerically more distinct in anti-TNF-naïve patients. Moreover, SEC demonstrated high retention rate, particularly in anti-TNF-naïve patients, thereby confirming previously reported real-world data on SEC from EuroSpA research collaboration network.2

Figure 1: Change of health in AS patients treated with SEC stratified by anti-TNF pretreatment

Figure 2: SEC treatment retention depending on anti-TNF pretreatment (Kaplan-Meier plot)


Disclosure: U. Kiltz, Abbvie, 2, 5, Biocad, 2, 5, Biogen, 2, 5, Chugai, 2, 5, Eli Lilly, 2, 5, Grünenthal, 2, 5, Janssen, 2, 5, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, 5, UCB, 2, 5; J. Brandt-Jürgens, Abbvie, 5, 8, Pfizer, 5, 8, Roche, 5, 8, Sanofi-Aventis, 5, 8, Novartis, 5, 8, Lilly, 5, 8, MSD, 5, 8, UCB, 5, 8, BMS, 5, 8, Janssen, 5, 8, Medac, 5, 8; P. Kästner, Chugai, Novartis, 1; E. Riechers, AbbVie, Chugai, Lilly, Jannsen, Novartis, Pfizer, Roche, UCB, 1, AbbVie, Chugai, Novartis, UCB, 1; D. Peterlik, Novartis Pharma GmbH, 1; H. Tony, AbbVie, 5, Astra-Zeneca, 5, BMS, 5, Chugai, 5, Janssen, 5, Lilly, 5, MSD, 5, Novartis, 5, Pfizer, 5, Roche, 5, Sanofi, 5.

To cite this abstract in AMA style:

Kiltz U, Brandt-Jürgens J, Kästner P, Riechers E, Peterlik D, Tony H. How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/how-do-tnf-alpha-inhibitors-in-medical-history-affect-patient-reported-outcomes-and-retention-in-ankylosing-spondylitis-patients-treated-with-secukinumab-in-real-world-german-observational/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-do-tnf-alpha-inhibitors-in-medical-history-affect-patient-reported-outcomes-and-retention-in-ankylosing-spondylitis-patients-treated-with-secukinumab-in-real-world-german-observational/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology